Navigation Links
Children's Tumor Foundation Announces FDA Accepts Submission for Selumetinib as Treatment for Neurofibromatosis and Grants Priority Review
Date:11/14/2019

AstraZeneca and MSD (Merck) announced today that the U.S. Food and Drug Administration (FDA) has granted acceptance to file status of its application for the MEK inhibitor selumetinib, for use in patients with plexiform neurofibromas, a common manifestation in the disease neurofibromatosis type one (NF1). The FDA’s acceptance of the application is a major milestone for selumetinib becoming the first ever approved treatment for NF patients. This follows previous designations from the FDA granting the treatment orphan drug status as well as breakthrough status, and now enters the drug into the FDA’s approval pipeline. The FDA also granted priority review, and a PDUFA (Prescription Drug User Fee Act) has been set for the second quarter of 2020.

This application follows comprehensive clinical testing of the drug in patients at the National Cancer Institute (NCI), a division of the National Institutes of Health (NIH). In those clinical trials, over 70% of NF patients with inoperable plexiform neurofibromas saw tumor size reduction anywhere from 20-55% in size. In addition to both visible and actual tumor reduction, patients reported higher-quality physical function, improved mobility, and enhanced emotional and psychological status.

The first use of MEK inhibitors as a potential treatment for NF tumors came from an early-stage discovery by Children’s Tumor Foundation (CTF)-funded researchers, who showed that the repurposed oncology drug selumetinib could affect NF tumor size. Positive early clinical results were first reported at CTF’s annual scientific NF Conference in 2015, as well as in a subsequent publication in the New England Journal of Medicine.

Collaborative efforts among the NCI, the NIH, the NFRP-CDMRP (Neurofibromatosis Research Program of the Congressionally Directed Medical Research Programs), NTAP (Neurofibromatosis Therapeutic Consortium), and CTF ensured that this ‘MEK Story’ proceeded efficiently and expeditiously through proactive and strategic coordination, which included patient input in the mix. A soon-to-be-published paper on this unique collaboration, and its potential application for other disease areas, will appear in EMBO Molecular Medicine. Other types of MEK inhibitors are also now in clinical trial, including mirdametinib from SpringWorks Therapeutics, a company which CTF helped spin off from Pfizer.

“Today’s announcement from AstraZeneca and MSD/Merck is a huge step towards our ultimate dream – approved treatments for neurofibromatosis,” said Annette Bakker, PhD, President of the Children’s Tumor Foundation. “We believe that FDA approval of this treatment will not only help our patients, but will also open the door to increased interest in NF, as a validation of the power of working together to find cures for patients who most need them.”

Founded in 1978, the Children’s Tumor Foundation is the world’s largest nongovernmental funder of all forms of neurofibromatosis research in the world. Its collaborative and open-data research model has catalyzed new discoveries and in recent years helped triple the number of clinical trials for NF, identified new drug candidates for both NF1 and NF2, and established a unique worldwide consortium focused on pain.

Neurofibromatosis is a genetic disorder that affects 1 in 3,000 births of all populations equally, and causes tumors to grow on nerves throughout the body. Its devastating effects can cause blindness, deafness, bone abnormalities, disfigurement, learning disabilities, disabling pain, and cancer.

To read the Astra Zeneca / MSD press release about today’s announcement, click here.

To read more about the MEK story collaboration, click here.

To view videos of the positive impact this treatment has on NF patients, watch Philip’s story here and Jane’s story here. Read the stories of other NF patients currently receiving this treatment here.

To learn more, visit the Children’s Tumor Foundation at ctf.org.

Read the full story at https://www.prweb.com/releases/children_s_tumor_foundation_announces_fda_accepts_submission_for_selumetinib_as_treatment_for_neurofibromatosis_and_grants_priority_review/prweb16723949.htm.


'/>"/>
Source: PRWeb
Copyright©2019 Vocus, Inc.
All rights reserved


Related medicine news :

1. NYC Injury Lawyers Block O'Toole & Murphy Hosted Their 2013 Autumn Wine Tasting Event To Benefit St. Jude Children's Research Hospital And It Was A Huge Success
2. Red Flags for Primary Teachers, Katie Johnson's Book about Children's Vision, Wins in The Great Midwest Book Festival Contest
3. UC Davis Children's Hospital Offers Access to Pediatric Subspecialty Care for Rural Newborns With PEANUT Program
4. SmartPractice Working with Phoenix Children's Hospital Art Project to Fund Childhood Cancer Research
5. Child Has Surgery at Wolfson Children's Hospital to Disconnect Left from Right Brain to Help Control Condition Causing Hundreds of Seizures a Day
6. Katie Johnson and Others Spoke About the Role of Children's Vision in Learning and Development at the 37th Annual WAEYC Fall Conference in Seatac, Washington in November
7. Electricity Maine Employees Donate Children's Books to Literacy Program
8. How Can University Educators Help Children's Vision? Katie Johnson Works with Graduate Students in Interactive Media and Design to Develop Vision Screening Tool
9. Hyatt Regency Boston Hotel's Room for Hope Raises $25,000 to Benefit Boston Children's Hospital
10. Terri Schiavo Life and Hope Network: Jahi McMath Supporters Pressing for Release from Children's Hospital Oakland
11. Save the Date for the 2014 Art & Antiques Show benefiting Wolfson Children's Hospital in Jacksonville, FL
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/4/2019)... ... December 04, 2019 , ... Eolas Therapeutics Inc. today ... use and dependence. The study will investigate safety and pharmacokinetics (PK) of AZD4041 ... orexin-1 (hypocretin-1) receptors that is being developed in collaboration with AstraZeneca. , “Smoking-related ...
(Date:12/2/2019)... , ... December 02, 2019 , ... ... solutions, has worked with EMD Serono, the North American branch of the healthcare ... . This site is designed to educate and inform patients, caregivers, the public, ...
(Date:12/2/2019)... , ... December 02, 2019 , ... ... efficiency and flexibility to the Sterile Processing Department. The elegant design provides a ... The P1000 has downward sliding doors that allow for manual loading that provides ...
(Date:11/30/2019)... ... November 28, 2019 , ... Planet 13 , a ... and dispensary operations, has received a Clio Cannabis Award in Brand Design for ... great accomplishment for our company and also for the talented creative team who ...
(Date:11/30/2019)... ... November 29, 2019 , ... As Cumberland ... teachers aren’t focusing on the potential for academic backslide but rather opportunities for ... textbooks or logging into GoogleClassroom as often during the break but might be ...
Breaking Medicine News(10 mins):
(Date:12/4/2019)... ... December 04, 2019 , ... Tenex ... minimally invasive technologies to treat chronic pain in soft and hard tissue, recently ... TX® technology. , Dr. Bernard Morrey, Chief Medical Officer of Tenex ...
(Date:12/2/2019)... ... December 02, 2019 , ... A ... for Michael, an intensive mental health facility, announced it has named Tim Ryan ... business development and national advocacy efforts. , "We are proud to announce that ...
(Date:12/2/2019)... ... December 02, 2019 , ... ... places to live, work, learn, and play. Striving to fulfill their crucial mission, ... rigorous national standards set by the Public Health Accreditation Board (PHAB). Today, PHAB ...
Breaking Medicine Technology: